| Abstract | Određene su koncentracije imunoglobulina A (IgA1 i IgA2) i imunoglobulina G (IgG1, IgG2, IgG3, IgG4)) u slini 31 bolesnika s aftama u akutnoj fazi i u remisiji bolesti, te u 20 zdravih ispitanika. Bolesnici s aftama još su razvrstani u dvije skupine: u one s minornim (19 ispitanika) i u one s majornim (12 ispitanika) aftama. Koncentracije IgG određene su enzimskim imunotestom, a koncentracije IgA radijalnom imunodifuzijom i izražene u mg (IgA), odnosno u g (IgG) po ml sline. Rezultati su statistički obrađeni Mann-Whitney U testom i Wilcoxonovim testom. U bolesnika s aftama u akutnoj fazi bile su povišena sva četiri podrazreda IgG (IgG1 62,3 vs. 20,8 g/ml, p<0,001; IgG2 134,6 vs. 65,9 g/ml, p=0,006; IgG3 24,6 vs. 5.7 g/ml, p<0,001; IgG4 29.2 vs. 10,5 g/ml, p=0,002) te IgA2 (133,8 vs. 99,2 mg/ml, p=0,021) u odnosu na zdrave ispitanike. Koncentracije svih podrazreda IgG bile su povišene u obje skupine u odnosu na vrijednosti u zdravih ispitanika, ali među skupinama nije bilo statistički značajne razlike. U bolesnika s majornim aftama koncentracije IgA nisu se razlikovale od onih u zdravih ispitanika, no u bolsnika s minornim aftama koncentracija IgA2 bila je viša od one u zdravih ispitanika (135,5 vs. 99,9 mg/ml, p=0,038). U bolesnika s aftama u remisiji, koncentracije IgG2, IgG3 i IgA2 ostale su povišene. Rezultati pokazuju promijenjene koncentracije salivarnih imunoglobulina u bolesnika s aftama, te da postoje razlike između bolesti u aktunoj fazi i remisiji, što bi moglo upućivati na ulogu salivarnih imunoglobulina u patogenezi i obrani od tih bolesti ili jednostavno odražavati promjene njihova tijeka. |
| Abstract (english) | Concentrations of IgA and IgG subclasses were determined in saliva of 31 patients with recurrent aphthous ulcerations (RAU) in acute phase and during the remission period, and the same values were determined in 20 healthy controls. Patients were grouped in two categories, one with the minor aphtous ulcerations (19 patients) and the other with major ones (12 patients). Concentrations of IgG were determined by enzyme-linked immunosorbent assay (ELISA), and concentrations of IgA by radial immunodiffusion. Results were expressed in mg (IgA) and g (IgG) per ml of saliva. The results were analyzed by Mann-Whitney U and Wicoxon tests. Patients with RAU showed elevation of all IgG subclasses (IgG1 62.3 vs. 20.8 g/ml, p<0,001; IgG2 134.6 vs. 65.9 g/ml, p=0,006; IgG3 24.6 vs. 5.7 g/ml, p<0,001; IgG4 29.2
vs. 10.5 g/ml, p=0,002) and IgA2 (133.8 vs. 99.2 mg/ml, p=0,021) compared to healthy controls. Concentrations of all IgG subclasses were elevated in patients with minor RAU and in those with major ones compared to healthy controls, but there was no difference in concentrations of IgG subclasses between the two patient subgroups. Concentrations of IgA in patients with major RAU showed no differences compared to healthy controls, but concentrations of IgA2 in patients with major RAU were elevated compared to healthy controls (135.5 mg/ml vs. 99.9 mg/ml, p=0.038). Patients with RAU in remission had concentrations IgG2, IgG3 and IgA2 elevated. The results presented show that concentrations of salivary immunoglobulins were changed and show that there were differences between acute phase of disease and remission, which might point to the role of salivary immunoglobulins in pathogenesis and immune defense |
